Ipilimumab and Nivolumab Followed by Adjuvant Nivolumab in Locally Advanced or Limited Metastatic Melanoma

NCT06566391 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

35

Enrollment

OTHER

Sponsor class

Conditions

Melanoma

Interventions

DRUG: Ipilimumab

Sponsor

European Institute of Oncology

Collaborators

[object Object]